Pneumagen is a clinical-stage biotech company that specializes in developing innovative solutions to combat viral respiratory tract infections (RTIs). Their flagship product, Neumifil, is a groundbreaking intranasal drug with broad-spectrum antiviral properties. Neumifil, an engineered multivalent Carbohydrate Binding Molecule (mCBM), is designed to prevent and treat a range of viral infections, including Influenza Virus (IFV), Respiratory Syncytial Virus (RSV), Human Rhinovirus (hRV), and Coronaviruses like SARS-CoV-2.

What sets Neumifil apart is its unique mechanism of action. By binding directly to sialic acid on host cells, this proprietary technology inhibits viral entry and provides effective prophylaxis against the pathogens. Developed using Pneumagen's cutting-edge GlycoTarge™ platform, Neumifil represents groundbreaking progress in the field of glycobiology.

Pneumagen's expertise extends beyond Neumifil, as they are actively leveraging their GlycoTarge™ platform to develop additional therapies targeting various infectious diseases. With a team of industry experts and a strong commitment to value creation, Pneumagen is at the forefront of revolutionizing disease management, reducing complications, and improving outcomes for patients with chronic lung diseases at risk of viral-induced exacerbations